春节假期落幕，A股即将开市。参考海外资产与港股的假期表现，有望成为预判板块轮动的关键风向标。快来看看最新消息！ 今日（2月23日），港股高开高走，全线大涨，为A股马年开门红营造积极氛围。 港股率先开市，全线飘红 哪些板块春节假期走强？ 消息面上，据新华社消息，我国科学家近日在光通信和6G领域取得突破性进展，在国际上率先实现光纤通信和无线通信系统间的跨网络融合，自主研发 的"光纤—无线一体化融合通信系统"的数据传输速率刷新纪录。该成果2月19日凌晨在线发表于《自然》。《自然》审稿人认为，这项工作"对融合光学和 太赫兹通信系统的进步作出重要贡献"。 开源证券近期研报称，展望2026年，AI"虹吸效应"显著，全球AI或继续共振。海外方面，谷歌、Meta等巨头不断上调AI资本开支指引，谷歌Gemini等大 模型Tokens消耗量大幅提升，AI正循环效应逐步凸显。国内方面，以字节跳动、阿里巴巴、腾讯等为代表的国内AI巨头或进入AI算力大规模投入期。看 好"光、液冷、国产算力"三大核心主线，同时建议重点关注AI应用、运营商、卫星互联网&6G等板块。 纵观整个假期，港股先抑后扬、震荡中不乏亮点，多只基金重仓港股大幅走强，既 ...

各大券商分析师春节"连轴转" 每经记者｜王海慜 每经编辑｜何小桃 赵云 宋思艰 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商的分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的连续七天新春专题路演，到中信证券聚焦AI大模 型的系列电话会，再到多家机构跟踪春节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 《每日经济新闻》记者注意到，今年春节加班路演已经成为各券商研究所的常态，无论是中小券商还是头部券商都在假期中继续"营业"，"加更"观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能概念股表现亮眼。2月20日和23日，恒生科技指数 走势先抑后扬，迎来马年"开门红"。 同时业内预计，美国此次关税裁定落地利好非美市场资产，叠加A股春节效应的历史正向表现，市场对马年节后"红包行情"的延续抱有较高期待。 截图来源：网络 最近，兴业证券策略首席张启尧的春节路演计划表在圈内刷屏：从大年初一至初七，他和团队同事一起每天15:00准时与投资者连线。 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、20 ...

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the supply-demand relationship will gradually improve, leading to performance recovery for companies in this sector [10][34]. Core Insights - The blood products industry is characterized by a clear long-term growth trajectory, supported by a favorable regulatory environment for plasma collection and an expanding product range among companies [12][34]. - Short-term performance has been impacted by supply-demand mismatches, with a notable decline in profitability observed in 2025 due to excess supply and price reductions [19][36]. - The report highlights the importance of white albumin and immunoglobulin (IVIG) as core products, with a stable demand expected despite recent price pressures [33][34]. Summary by Sections Market Review - The report notes a decline of 0.85% in the medical index, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 sectors [6]. - The top-performing stocks in the medical sector include Aidi Te, Zhendai Medical, and Olin Bio, while the worst performers include Beixin Life and Huayuan Bio [6]. Industry and Stock Events - The report emphasizes the recovery of plasma collection activities post-pandemic, which has led to increased supply and a shift in the market dynamics for blood products [19][26]. - The report identifies key companies to watch, including Tian Tan Biological and Bo Ya Biological, as they are expected to benefit from the industry's growth [12][34]. Overall Perspective and Investment Themes - The report suggests focusing on innovative drugs, medical devices, and the blood products sector, highlighting the potential for significant growth driven by domestic differentiation and international expansion [10][12]. - The report also discusses the ongoing consolidation in the industry, particularly among state-owned enterprises, which may enhance market concentration and operational efficiencies [46]. Supply and Demand Dynamics - The report indicates that the supply of blood products is expected to tighten in 2026 due to a slowdown in plasma collection growth and a decrease in imported white albumin supply [30][34]. - Demand for white albumin remains robust, with sales showing signs of stabilization despite recent challenges [33][34]. Future Outlook - The report anticipates a gradual return to a balanced supply-demand relationship in the blood products industry, which could lead to improved financial performance for key players [34][36]. - The potential for new product introductions and market expansions is highlighted as a significant driver for future growth in the sector [12][34].

Investment Rating - The report maintains a positive outlook on the blood products industry, suggesting that the sector has clear long-term growth potential due to increasing supply and demand elasticity [12][19][36]. Core Insights - The blood products industry is expected to benefit from a more relaxed approval process for plasma collection stations during the 14th Five-Year Plan, leading to increased production capacity and a diverse range of products [12][19]. - The report highlights a significant shift in the industry from a supply surplus to a supply-demand balance, with expectations for improved performance in 2026 as supply constraints tighten and demand remains stable [36][34]. - Key companies to watch include TianTan Biotech, BoYa Bio, and HuaLan Bio, which are expected to see performance improvements as the market stabilizes [12][36]. Summary by Sections Market Review - The report notes that the CITIC pharmaceutical index fell by 0.85%, underperforming the CSI 300 index by 1.22 percentage points, ranking 21st among 30 primary industries [6]. - The top-performing stocks in the sector included AidiTe and ZhenDe Medical, while stocks like BeiXin Life and HuaYuan Bio faced significant declines [6][12]. Industry and Stock Events - The blood products sector has experienced a prolonged adjustment period, with a cumulative decline of 18.1% since early 2025, significantly underperforming the broader pharmaceutical sector [16]. - The report indicates that the performance of major blood product companies has varied, with some like WeiGuang Bio and HuaLan Bio performing better than the sector average [16]. Overall Perspective and Investment Themes - The report emphasizes the transition from a quantity-driven to a quality-driven approach in the innovative drug sector, suggesting a focus on differentiated products and international expansion [10]. - In the medical device sector, there is a notable recovery in bidding volumes for imaging equipment, with companies like MaiRui and LianYing expected to benefit from ongoing upgrades [10]. - The report also highlights the importance of the CXO and life sciences services sectors, predicting a recovery in domestic investment and a return to high growth rates [10]. Blood Products - The blood products industry is characterized by a clear growth trajectory, with both supply and demand expected to show significant elasticity [12][19]. - The report suggests that the industry will see improved performance due to a combination of increased plasma collection and a tightening supply situation, which is expected to stabilize prices and enhance profitability for key players [36][34].

Core Viewpoint - The Hong Kong stock market showed strong performance during the Spring Festival holiday, providing a positive reference for the A-share market as it prepares to open. The performance of overseas assets and Hong Kong stocks during the holiday is expected to be a key indicator for sector rotation in the A-share market [1][9]. Group 1: Market Performance - The Hong Kong stock market experienced a significant rally, contributing to a positive atmosphere for the A-share market's opening [1][9]. - During the holiday, the Hong Kong stock index fluctuated but ultimately rose, while the U.S. stock index saw only slight increases [2][10]. - Gold prices showed a four-day winning streak, indicating a strong performance in the precious metals sector [2][11]. Group 2: Sector Highlights - The Hong Kong market displayed structural trends, with sectors such as technology, internet, consumer electronics, and lithium batteries leading the gains. Notable stocks included Meituan, Tencent, and Alibaba [3][11]. - The optical fiber and cable leader, Longi Fiber Optic, saw its stock price double this year, driven by increased demand for high-fiber-count cables due to AI data center construction [12]. - Shipping and port stocks rose significantly due to geopolitical tensions, with China Merchants Energy's stock increasing nearly 90% since the beginning of the year [12]. Group 3: Fund Performance - Several funds heavily invested in Hong Kong stocks saw substantial gains, particularly in sectors like AI hardware, gold, innovative pharmaceuticals, and oil transportation, with some stocks rising over 10% during the A-share market's closure [11][12]. - Some innovative pharmaceutical companies in Hong Kong, such as Hang Seng Biotechnology and Hang Seng Healthcare, reported year-to-date gains exceeding 10% [4][13]. Group 4: Future Outlook - Analysts expect structural opportunities in the A-share market to continue, with resource products and AI sectors remaining the main focus for capital [15]. - The ongoing geopolitical tensions are likely to sustain demand for gold, with expectations of a continued bull market for gold over the next 2-3 years [15][16]. - Investment strategies are suggested to focus on high-growth sectors like AI hardware and applications, as well as undervalued sectors that may experience fundamental improvements and valuation recovery [17].

一、为什么我们总被行情"打脸"？ 最近刷到不少关于A股春节行情的分析，从券商研报到股民讨论，几乎都在说节后上涨概率高，很多人凭着往年的直觉，要么节前急着追涨热门的消费、科 技股，要么干脆满仓躺平等节后"红包"，结果往往事与愿违——去年有朋友看着节前某消费股连续3天飘红就冲进去，节后反而阴跌了半个月；还有人觉得 节后肯定普涨，拿着一堆冷门股一动不动，眼睁睁看着别人手里的票悄悄起飞。其实这就是我们普通人最容易踩的主观误区：靠经验、直觉甚至情绪做判 断，却忽略了市场里真正起作用的，是资金的真实交易行为。而现在，量化大数据的发展，已经能帮我们跳出这种直觉陷阱，用客观数据看清行情背后的逻 辑。 | | | | 年份 | 大年初一 | 年前 20 个 | 年前 10个 | 年前5个交 | 年前1个交 | 年后1个交 | 年后5个交 | 年后 10个 | 年后 2 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 交易日 | 交易日 | 易日 | 易日 | 易日 | 易日 | 交易日 | 交易 | | 2016 | 2016/2/8 ...

阿里、腾讯、美团等被总结为建议调出的"老登恒生"成分股。同时，恒生生物科技指数也在当日逆市收 涨0.96%，另外，石油股也出现走强。 值得留意的是，虽然港股互联网主题ETF、恒生科技ETF等节前资金流入最多的ETF并未迎来涨势，但 表现强势的个股也有公募基金的布局身影，次新股以打新的方式布局，而表现强势板块则在此前已有主 动权益基金的加仓迹象。 2月22日，节后首个交易日，恒指和恒生科技虽然没有收涨，但AI概念股的涨势如期而至。 2月20日，港股三大指数集体收跌。其中，恒生科技收跌2.91%，恒生指数收跌1.10%，而恒生国企指数 收跌1.22%。相较于恒生科技的继续下挫，港股上市的AI概念次新股却迎来上涨，网友也出现了调整恒 生科技部分成分股的建议。 小米、中芯国际、比亚迪、腾讯、快手等成分股也在去年四季度被主动权益基金减持，不过，美团在去 年四季度得到主动权益基金增持超过1700万股。 石油、创新药板块走强 港股AI概念股大涨 截至2月20日收盘，智谱延续强势表现，收涨42.72%，报725港元；MiniMax也同样收涨14.52%，报970 港元。两大AI龙头盘中最高市值双双突破3000亿港元，与上市初 ...

Market Outlook - The A-share market is expected to experience a low-volatility trend with a long-term decline in market volatility [2] - The upward trend in the stock market is not yet over, indicating further potential for growth [2] - A-shares are anticipated to maintain a fluctuating upward trend, with the importance of fundamentals increasing after a valuation adjustment [2][3] Capital Flow - The demand for asset allocation among domestic residents has been activated by profit effects, with various medium- to long-term funds entering the market, suggesting an active capital flow in 2026 [2][3] - Incremental capital is expected to cover a broader range, driven by increasing motivation among individual investors to enter the market [3] - Public funds and insurance capital are likely to continue increasing their allocation to equity assets, reshaping global capital flow logic [4] Key Investment Sectors - Key sectors to focus on include: - Non-ferrous metals, chemicals, and new energy [2] - Technology growth, manufacturing expansion, cyclical consumption transformation, and U.S. stocks [2] - New energy, non-ferrous metals, basic chemicals, oil and petrochemicals, non-bank financials, military industry, and machinery [3] - AI, new energy, military industry, innovative pharmaceuticals, price increase chains, and overseas expansion chains [4] - Technology innovation themes and consumption sectors [4] - TMT and advanced manufacturing sectors, with potential shifts towards cyclical and financial sectors [4]

新春伊始，万象更新，A股市场即将步入新征程。站在马年的起点，多家一线私募机构相继发布年度策 略，勾勒对后市的乐观预期与审慎布局。 市场主线切换：从全面修复到业绩为王 源乐晟资产提示，尽管结构性行情延续，但波动风险可能加剧。一方面，外部因素或引发市场短期波 动；另一方面，AI行业尤其是大模型公司将进入实绩检验阶段，若过程遇阻，将会引发板块调整。 核心赛道布局：捕捉"核心资产2.0" 面对全新的市场环境，如何布局才能捕捉到核心机会？ 星石投资称，2026年核心资产或迎来系统性重估，业绩有望成为主要驱动力量，带动市场再上台阶。重 点关注两大主线，一是以人工智能、创新药、机械设备、军工等为代表的高景气趋势的产业投资；二是 以交通运输、可选消费、房地产等为代表的供需关系改善的行业投资。 仁桥资产表示，在下半场行情演绎中，需要克制冲动、降低预期。2026年的投资，仁桥资产从五个大方 向展开：重视低估值股票系统性重定价的可能；AI端侧和应用仍需重视；2026年消费大概率将企 稳；"反内卷"具有战略性意义，短期效果会有分化；关注从"全球定价、安全出海"到"全球投资、服务 本地"的转变。 宁涌富基金表示，重点关注四大领域：一是 ...

Core Viewpoint - The Chinese economy is entering a new development stage in 2026, with A-shares showing signs of a "spring rally" driven by three main factors: policy direction, liquidity environment, and industry trends [1][2]. Group 1: Market Dynamics - The current market is characterized by a neutral to slightly hot sentiment, with growth sectors still having low valuations [2]. - The upward trend in the stock market is expected to continue, supported by favorable policies, a loose liquidity environment, and ongoing industry trends [2]. - Key macroeconomic observations include the importance of policy guidance and liquidity trends, which are crucial for stock market valuations [2]. Group 2: Policy and Liquidity - Both domestic and international policies are supportive of the stock market, which is seen as a vital tool for boosting consumption and restoring consumer confidence [2]. - The Federal Reserve is expected to lower interest rates to around 3% in 2026, while domestic liquidity remains ample with potential for rate cuts and reserve requirement reductions [2]. Group 3: Industry Trends - Two main industry directions benefiting from policy support are technological innovation and stimulating domestic demand [3]. - The AI sector is highlighted as a core area of competition, with significant investments expected to drive demand across the computing power supply chain, including GPUs and storage [3][4]. - The development rhythm in the industry shows a clear pattern of "hardware leading, applications following," with AI applications entering a rapid growth phase [4]. Group 4: Investment Opportunities - Investment opportunities in the AI sector are primarily focused on computing power, with a need to monitor downstream demand growth and capital expenditure trends [5]. - Specific segments within the computing power direction, such as raw materials and chips, are expected to have significant performance potential [5]. - The second key area for stimulating domestic demand includes opportunities in consumer sectors, particularly in the real estate market, where signs of recovery are emerging [6]. Group 5: Pharmaceutical Sector - The outlook for the consumer and innovative pharmaceutical sectors is cautiously optimistic, with valuations having adjusted and entering a more favorable investment zone [6]. - Investors are encouraged to seek innovative pharmaceutical companies with global competitiveness, especially those with strong product offerings and positive sales trends [6].